Sun Pharmaceutical Industries Ltd
Thu 13/03/2025,15:59:29 | NSE : SUNPHARMA
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 1672.00
Previous Close
₹ 1676.85
Volume
1666929
Mkt Cap ( Rs. Cr)
₹403916.05
High
₹ 1687.15
Low
₹ 1663.45
52 Week High
₹ 1960.35
52 Week Low
₹ 1377.20
Book Value Per Share
₹ 288.06
Dividend Yield
0.80
Face Value
₹ 1.00
What’s Your Call?
Collective community sentiment on Sun Pharmaceutical Industries Ltd
Your Vote -
Buy
70.76%
Hold
17.60%
Sell
11.65%
70.76%
25581 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
0%
Sell Order Quantity
100%
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Bid Price
Qty
1683.45
61
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
61
Option Chain
Analyzes market sentiment, predicts Sun Pharmaceutical Industries Ltd' movement.
Call Price | Open interest | Strike Price | Put Price | Open interest |
---|
News
Media spotlight triggers stock stock attention, sentiment.
-
Sun Pharma. - General Updates
-
Sun Pharma. - Announcement under Regulation 30 (LODR)-Updates on Acquisition
-
Sun Pharma. - Acquisition-XBRL
-
Sun Pharma. - General Updates
-
Sun Pharma to acquire checkpoint therapeutics for up to $355 million
-
Sun Pharma. - Announcement under Regulation 30 (LODR)-Acquisition
-
Sun Pharma. - Investor Presentation
-
Sun Pharma. - Announcement under Regulation 30 (LODR)-Investor Presentation
-
Sun Pharma. - Notice Of Shareholders Meetings-XBRL
-
Sun Pharma. - Shareholders meeting
-
Sun Pharma. - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
-
Sun Pharma. - Press Release
-
Sun Pharma. - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Sun Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Sun Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates
-
Sun Pharma. - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
-
Sun Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates
-
Sun Pharma. - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Re
-
Sun Pharma. - Action(s) taken or orders passed
-
Sun Pharma. - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Re
-
Sun Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Sun Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates
-
Sun Pharma. - Press Release
-
Sun Pharma. - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Sun Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates
-
Sun Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Sun Pharma. - Sustainability Report For The Financial Year 2023-24
-
Sun Pharma. - Updates
-
Sun Pharma. - Updates
-
Sun Pharma. - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Ap
-
Sun Pharma. has declared 1050% Interim dividend for the financial year March 2025
-
Sun Pharma. - Q3FY25 Investor Call Audio Recording
-
Sun Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates
-
Sun Pharma. - Integrated Filing (Financial)
-
Sun Pharma. - Integrated Filing- Financial
-
Sun Pharma. Q3 net profit jumps 63.74% at Rs 1181.05 cr
-
Sun Pharma. - Outcome of Board Meeting-XBRL
-
Sun Pharma. - Dividend
-
Sun Pharma. - Corporate Action-Board approves Dividend
-
Sun Pharma. - Outcome Of The Board Meeting Held Today I.E. January 31, 2025
-
Sun Pharma. - Financial Result Updates
-
Sun Pharma. - Shareholders meeting
-
Sun Pharma. - Shareholder Meeting / Postal Ballot-Outcome of Court Convened Meeting
-
Sun Pharma. has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2024
-
Sun Pharma. - Acquisition-XBRL
-
Sun Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Sun Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates
-
Sun Pharma. - Record Date
-
Sun Pharma. - Intimation Under Regulation 42 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Re
-
Sun Pharma. - Board Meeting Intimation
-
Sun Pharma. - Record Date
-
Sun Pharma. - General Updates
-
Sun Pharma. - Announcement under Regulation 30 (LODR)-Acquisition
-
Sun Pharma. - Corporate Action-Board to consider Dividend
-
Sun Pharma. - Board Meeting Intimation for Approval Of Financial Results For Quarter And Nine Months Ended December 31, 2024
-
Sun Pharma. - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Sun Pharma. - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Sun Pharma. - Sale or disposal-XBRL
-
Sun Pharma. - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Sa
-
Sun Pharma. - General Updates
-
Sun Pharma. - Trading Window-XBRL
-
Sun Pharma. - Trading Window
-
Sun Pharma. - Copy of Newspaper Publication
-
Sun Pharma. - Notice Of Shareholders Meetings-XBRL
-
Sun Pharma. - Shareholders meeting
-
Sun Pharma. - Notice Of The National Company Law Tribunal Convened Meeting Of Equity Shareholders On January 21, 2025
-
Sun Pharma to acquire checkpoint Therapeutics
-
Sun Pharma unit Taro to acquire stake in Antibe Therapeutics
-
Stock Update: Sun Pharmaceuticals Industries Ltd Q2FY2025 Results Review
-
Sun Pharmaceutical Industries
-
Sun Pharma signs agreement with Swiss-Italian
-
Stock update: Sun Pharmaceutical Industries
-
Sun Pharma introduces a novel treatment, STARIZO
-
Sun Pharma gets USFDA approval for Alopecia treatment drug.
-
Sun Pharmaceutical Industries
-
Stock Update: Sun Pharmaceutical Ltd
-
Sun Pharmaceutical Industries
-
Sun Pharmaceuticals Industries
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharma announces approval of Winlevi in Australia
-
Stock Update: Sun Pharma
-
Sun Pharmaceutical Industries
-
Sun Pharma to acquire 16.33% stake in Surgimatix for $3.05 m
-
Taro announces merger agreement with Sun Pharma
-
Sun Pharmaceutical Industries
-
Sun Pharma signs agreement with Bayer
-
Sun Pharma
-
Sun Pharmaceuticals Industries
-
Sun Pharmaceutical Industries
-
Sun Pharma
-
Stock Update: Sun Pharma
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries Limited: Result Update
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharma announces USFDA filing acceptance of NDA for Deuruxolitinib
-
Sun Pharma
-
Sun Pharma Canada launches Winlevi a novel topical treatment for acne.
-
Sun Pharma arm enters into a license agreement with Pharmazz In
-
Sun Pharma
-
Sun Pharmaceutical
-
Sun Pharmaceutical Industries
-
Sun Pharma
-
Sun Pharma acne cream WINLEVI gets HealthCanada approval
-
Sun Pharmaceutical Industries
-
Sun Pharma Industries
-
Sun Pharma licensing agreement for commercializing Philogen specialty product
-
Sun Pharma board proposes to buy remaining stake in Taro
-
Sun Pharma board proposes to buy remaining stake in Taro
-
Sun Pharmaceuticals Industries
-
Sun Pharmaceutical Industries
-
Sun Pharma launches CEQUA a novel therapy for Dry Eye Disease in India
-
Sun Pharmaceutical Industries
-
Sun Pharma
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharma
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Inddustries
-
Sun Pharma to acquire minority stake in 2 Companies
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharma announces USFDA approval for Generic Lenalidomide Capsules
-
Sun Pharma Q3FY23 Results
-
Sun Pharmaceutical Industries
-
Sun Pharma acquires Disperzyme and Phlogam brands in India
-
Sun Pharma
-
Sun Pharma
-
Sun Pharmaceutical Industries
-
Sun Pharma launches Palbociclib, a novel targetted therapy for advanced Breast Cancer
-
Sun Pharma
-
Stock update – Sun Pharmaceuticals
-
Sun Pharma
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharma, Cosmo Pharma expand agreement for Winlevi
-
Stock Update - Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharma arm acquires Uractiv portfolio from Fiterman Pharma in Romania
-
Sun Pharma launches Brillo a oral lipid-lowering drug in India
-
Sun Pharmaceuticals Industries
-
Sun Pharmaceutical Industries
-
Sun Pharma Halol unit gets 10 observations from USFDA
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Aurobindo, Sun Pharma
-
Sun Pharmaceutical Industries
-
Sun Pharma to launch Vortioxetine version in India
-
Sun Pharma
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharma and Aurobindo Pharma
-
Sun Pharma arm to acquire Alchemee from Galderma for $90 million
-
Sun Pharmaceutical Industries
-
Sun Pharma Q3FY22 results
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharma receives DCGI approval for Molxvir (Molnupiravir) in India
-
Sun Pharmaceutical Industries
-
Sun Pharma gets USFDA approval for Amphotericin B injection
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharma introduces skin cream in US
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharma launches Chericof 12 in India
-
Sun Pharma
-
Sun Pharma's foray into Nutrition Bar segment with the launch of Revital NXT
-
Sun Pharma, Cassiopea announce the expiry of the HSR Act process
-
Sun Pharmaceutical Q1FY22 Result Update
-
Sun Pharma: Q1FY22 results
-
Sun Pharma: Q1FY22 results
-
Sun Pharmaceutical Industries
-
Sun Pharma
-
Sun Pharma settles patent litigation with Celgene Corporation
-
Sun Pharmaceutical Industries
-
Sun Pharma enters into a licence agreement with Ferring Pharma
-
Sun Pharmaceutical Industries : Q4FY2021 Result update
-
Sun Pharmaceutical Industries
-
Sun Pharma
-
Sun Pharmaceutical Industries
-
Sun Pharma signs voluntary licensing agreement with Eli Lilly
-
Lupin, Sun Pharma, Jubilant Lifesciences
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries Limited: Stock Update
-
Sun Pharmaceutical
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharma launches website for its long-term care portfolio in the US
-
Sun Pharmaceutical Industries
-
Sun Pharma to launch Epilepsy drug Brivaracetam in India
-
Sun Pharma, Alkem Labs, Ajanta Pharma
-
Sun Pharmaceutical Industries
-
Sun Pharma: Subsidiary company
-
Sun Pharmaceutical Industries Ltd
-
Taro Pharma
-
Sun Pharma
-
Sun Pharmaceutical Industries: Stock Update
-
Sun Pharma
-
Sun Pharmaceuticals
-
Sun Pharmaceutical Industries
-
Sun Pharma
-
Sun Pharmaceutical Industries: Q2FY2021
-
Sun Pharma (Taro Results)
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharma announces launch of ILUMYA
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharma launches Fluguard in India at Rs. 35 tablet
-
Sun Pharmaceutical Industries
-
Sun Pharmaceuticals
-
Sun Pharmaceutical Industries
-
Sun Pharma
-
Sun Pharma
-
Sun Pharma arm to acquire Aquinox Pharmaceuticals
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharma gets Japan regulator nod for Psoriasis Drug
-
Sun Pharmaceutical Industries
-
Sun Pharma, Hikma enter into exclusive licensing agreement for ILUMYA
-
Sun Pharma
-
Sun Pharmaceutical Industries
-
Sun Pharma initiates Phase II clinical trial on AQCH
-
Sun Pharmaceutical Industries, SPARC
-
SPARC, Sun Pharma enter into a worldwide license agreement for SCD-044
-
Sun Pharmaceutical Industries
-
Sun Pharma
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharma
-
Sun Pharma approves buyback of 4 crore shares
-
Sun Pharmaceutical surges as board to consider buyback
-
Sun Pharma
-
Sun Pharma
-
Sun Pharmaceutical
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharma
-
Sun Pharma
-
Sun Pharma, Subsidiary
-
Sun Pharma
-
Sun Pharma
-
Sun Pharma
-
Sun Pharma falls as Halol facility gets eight observations
-
Sun Pharma
-
Sun Pharma
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharmaceuticals
-
Sun Pharmaceutical Industries
-
Sun Pharmaceutical Industries
-
Sun Pharma
-
Sun Pharma
-
Sun Pharmaceuticals Industries Ltd
-
Sun Pharma, AstraZeneca to develop oncology products for China
-
Sun Pharmaceutical Industries
-
Sun Pharma launches CEQUA for treatment of dry eye disease in US
-
SEBI clears allegations against Sun Pharma
-
Sun Pharma gains after clearing SEBI enquiry
-
Taro gets USFDA approval for Azelaic Acid Gel
-
Sun Pharma gets USFDA nod for Dapagliflozin Drug
-
Sun Pharma arm ink pact with China Medical System
-
Sun Pharma gets USFDA nod for Erlotinib
-
Sun Pharma introduces Ezallor Sprinkle capsules in the US market
-
Sun Pharmaceutical announces interim results from a Phase 2 study
-
Sun Pharma’s US subsidiary to announce Q4 numbers
-
Sun Pharma launches Ready-to-Infuse INFUGEM in the US
-
SEBI seeks explanation from Sun Pharmaceutical
-
Taro Pharma will report Q3FY2019 numbers today
-
Sun Pharmaceutical gets USFDA nod for Lialda
-
Sun Pharma gets USFDA nod to treat bowel disease
-
Sun Pharma Clarification
-
Sun Pharma recalls 3,918 cartons
-
Sun Pharmaceuticals hits 52-week low
-
Management clarifies, Sun Pharma rises
-
Sun Pharma to acquire Pola Pharma Inc. in Japan
-
Sun Pharma to acquire Pola Pharma in Japan
-
Sun Pharma launches psoriasis treatment drug Ilumya in the US
-
USFDA updates Halol plant’s status to NAI
-
Sun Pharma gets Australia nod for psoriasis drug
-
Sun Pharma gets another nod for Ilumya
-
Sun Pharma bags EC approval for ILUMETRI
-
Sun Pharma, SPARC gets USFDA nod of xelpros
-
USFDA inspects Sun Pharma's Mohali plant
-
Sun Pharma to buy stake in Israel firm
-
Sun Pharma falls after USFDA issues for Halol facility
-
USFDA issues Form 483 with six observations
-
Sun Pharma launches Volini Maxx
-
USFDA surprise inspection at Sun Pharma's Halol facility
-
Sun Pharma up on securing USFDA nod of CEQUA
-
Sun Pharma numbers in line with expectation
-
Sun Pharma launches Kapspargo Sprinkle in US
-
Sun Pharma introduces Kapspargo Sprinkle in USA
-
Sun Pharma launches generic Glumetza tablets in U
-
Sun Pharma gets USFDA nod for Naproxen Sodium
-
Sun Pharma gets USFDA nod for INFUGEM™ Injection
-
Sun Pharma unit files lawsuit against German firm
-
Sun Pharma Halol out of USFDA regulatory hurdles
-
Sun Pharma up on EIR from USFDA for Halol facility
-
Sun Pharma company receives EIR
-
Sun Pharma receives prestigious CSR Award
-
Sun Pharma company launches gGlumetza in US
-
Sun Pharma introduces Welchol tablets in US
-
Taro Pharma reports growth in profit for Q4FY2018
-
Sun Pharma Company’s Subsidiary Taro to report its Q4FY2018 numbers today
-
Sun Pharma gets USFDA approval for Paliperidone
-
Product approval positive for Sun Pharma
-
Sun Pharma gets USFDA nod for plaque psoriasis drug
-
Sun Pharma gets USFDA approval for ILUMYA
-
No critical observations but warning letter overhang continues for Sun Pharma
-
Halol Form 483 observations procedural in nature for Sun Pharma
-
USFDA inspection of Sun Pharma Halol plant to complete today
-
Sun Pharma settles patent litigation with Allergan, Ironwood
-
Sun Pharma gets tentative approval for Tadalafil Tablets
-
Sun Pharma revokes pledge of 1 crore shares
-
Sun Pharma voluntarily recalls two lots of Riomet
-
Sun Pharma recalls Riomet drug
-
Sun Pharma’s Baska unit's inspection completed by USFDA
-
Sun Pharma's Q2 numbers below estimates
-
Sun Pharma’s Taro gets USFDA nod for allergy treatment drug
-
Sun pharma’s subsidiary Taro to report Q2FY2018 numbers today
-
Sun Pharma: Taro Gets USFDA approval for Dapsone Gel - positive
-
Sun Pharma: Dadra plant receives EIR, regulatory risk reduces
-
Sun pharma’s Dadra facility gets EIR – Positive
-
Sun Pharma gets USFDA nod Cholesterol drug
-
Sun Pharma gets USFDA nod Cholesterol drug
-
Taro reports disappointing Q1FY2018 results
-
Sun Pharma up after settling antitrust litigation in US
Key fundamentals
Evaluate the intrinsic value of Sun Pharmaceutical Industries Ltd stock
Name | March-24 | March-23 | March-22 | March-21 | March-20 |
---|---|---|---|---|---|
Assets | 34741.01 | 31341.03 | 29456.66 | 31525.7 | 30141.18 |
Liabilities | 34741.01 | 31341.03 | 29456.66 | 31525.7 | 30141.18 |
Equity | 239.93 | 239.93 | 239.93 | 239.93 | 239.93 |
Gross Profit | 5587.61 | 6472.86 | 2907.52 | 2936 | 2711.65 |
Net Profit | 2858.18 | 1690.72 | -99.99 | 2139.7 | 3211.14 |
Cash From Operating Activities | -292.42 | 507.08 | 7636.36 | 1737.25 | 1305.85 |
NPM(%) | 14.09 | 8.12 | -0.64 | 16.71 | 25.62 |
Revenue | 20275.17 | 20812.14 | 15585.98 | 12803.21 | 12531.93 |
Expenses | 14687.56 | 14339.28 | 12678.46 | 9867.21 | 9820.28 |
ROE(%) | 4.13 | 2.44 | -0.14 | 3.09 | 4.64 |
Corporate Action
XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
---|---|---|---|---|
06 Feb 2025 | 10.5 | 1050 | 0.8 | 1763.3 |
12 Jul 2024 | 5 | 500 | 0.8 | 1539.3 |
09 Feb 2024 | 8.5 | 850 | 0.8 | 1329.35 |
08 Feb 2023 | 7.5 | 750 | 0.8 | 1035.45 |
19 Aug 2022 | 3 | 300 | 0.8 | 860.6 |
09 Feb 2022 | 7 | 700 | 0.8 | 834.5 |
23 Aug 2021 | 2 | 200 | 0.8 | 699.5 |
09 Feb 2021 | 5.5 | 550 | 0.8 | 586.2 |
19 Aug 2020 | 1 | 100 | 0.8 | 450.9 |
17 Feb 2020 | 3 | 300 | 0.8 | 430.65 |
20 Aug 2019 | 2.75 | 275 | 0.8 | 412.75 |
17 Sep 2018 | 2 | 200 | 0.8 | 466.45 |
18 Sep 2017 | 3.5 | 350 | 0.8 | 507.45 |
08 Sep 2016 | 1 | 100 | 0.8 | 762.75 |
21 Oct 2015 | 3 | 300 | 0.8 | 841.75 |
11 Sep 2014 | 1.5 | 150 | 0.8 | 802.6 |
19 Sep 2013 | 2.5 | 250 | 0.8 | 996.25 |
14 Aug 2012 | 4.25 | 425 | 0.8 | 669.7 |
4.25 | 425 | 0.8 | 565.75 | |
02 Sep 2011 | 3.5 | 350 | 0.8 | 464.4 |
09 Sep 2010 | 13.75 | 275 | 0.8 | 1548.2 |
21 Aug 2009 | 13.75 | 275 | 0.8 | 1216.9 |
25 Aug 2008 | 10.5 | 210 | 0.8 | 1402.7 |
15 Mar 2007 | 6.75 | 135 | 0.8 | 969.05 |
06 Sep 2006 | 5.5 | 110 | 0.8 | 722.3 |
19 Sep 2005 | 3.75 | 75 | 0.8 | 622.75 |
10 Dec 2004 | 3.25 | 65 | 0.8 | 508.1 |
0 | 130 | 0.8 | 712 | |
24 Sep 2003 | 5 | 100 | 0.8 | 289.45 |
07 Oct 2002 | 0 | 0 | 0.8 | 573.9 |
20 Aug 2002 | 5 | 50 | 0.8 | 559.35 |
0 | 0 | 0.8 | 650.4 | |
17 Jul 2001 | 0 | 50 | 0.8 | 517.45 |
0 | 40 | 0.8 | 735 | |
0 | 20 | 0.8 | 1204.35 | |
0 | 60 | 0.8 | 459.75 | |
0 | 60 | 0.8 | 351.45 | |
0 | 35 | 0.8 | 250.25 |
Peers
Other companies within the same industry or sector that are comparable to Sun Pharmaceutical Industries Ltd
Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
---|---|---|---|---|---|---|
Albert David Ltd | 808.20 | -1.14 | 11.41 | 961.01 | 1321.50 | 1.42 |
Lotus Eye Hospital and Institute Ltd | 57.06 | -0.77 | 237.75 | 3501.78 | 14.01 | 0.88 |
Vaishali Pharma Ltd | 12.12 | -5.90 | 606.00 | 1804.95 | 2.31 | 0.00 |
Astec Lifesciences Ltd | 653.90 | -5.55 | 0.00 | 3301.88 | -239.30 | 0.00 |
Company Info
1983 - The Company was incorporated as a partnership firm by Dilip Sanghvi & his family to manufacture pharmaceutical formulation at Vapi, Gujarat. It was converted into a public Ltd. Company effective 1st March. The was promoted by Dilip Sanghvi. The Company specialises in selected therapeutic segment to psychiatry, cardiology, neurology and gastroenterology. 1994 - The Bulk drug plant at Panoli was commissioned. The second formulation plant at Silvana was commissioned in April. - During October, the company undertook to enhance the production capacity of bulk drugs at Panoli from 62,000 Kgs. p.a. to 92000 Kgs. p.a. Also formulation unit was to be enhanced to 1800 millions tablets p.a. from 570 million tablets p.a. - The Company proposed to modernise the formulation unit at Vapi and increase its capacity from 480 million tablets to 1440 million tablets p.a. It was also proposed to set up additional facilities at the R&D centre SPARC. - 71,85,000 No. of equity shares issued to promoters etc. 1995 - In the synergy division two more products viz. `Clofranil SR and Syndopa CR were introduced. - The Company entered into a MOU with Knoll Pharmaceuticals Ltd. for acquisition of their Ahmednagar unit manufacturing bulk drugs. - 35,92,500 No. of equity shares allotted as bonus shares in prop 1:2. 3,23,400 Rights shares issued at a premium of Rs 130 per shares.During October 1994, the capital issued 37,00,300 No. of equity shares of Rs 10 each at a premium of Rs 140 per share to the public. 1996 - 18 new products were launched across the company's six focused marketing divisions and 4 more line extension including drug delivery systems were launched. - The Company acquired controlling stake in MJ Pharmaceuticals Ltd. - SPIL and its group company Virtuous Finance Ltd., which are the the major shareholders of MJPL with more than 50 per cent of shareholding, had signed a MoU with erstwhile promoters the Shah family, on November 1. 1997 - The Company acquired 78,36,000 No. of equity shares of Rs 10 each. - The Chennai based Tamil Nadu Dadha Pharmaceuticals Co. Ltd. was merged with the company in the ratio of 4:1 effective 1st April. With this, IDPL brings to sun pharma extensive product strengths across the areas of gynaecology, fertility, oncology, pain mengeners and duaesthelics. - Sunkalp Laboratories Ltd., Sun Pharma Industries Ltd., Russia & Sun Pharma Global Inc. are all subsidiaries of the Company. - 4,13,633 No. of equity shares allotted to erstwhile shareholders of Tamil Nadu, Dadha Pharmaceuticals pursuant to a scheme of amalgamation. - The boards of Tamilnadu Dadha Pharmaceuticals Ltd. (TDPL) and Sun Pharmaceuticals Ltd. have approved a 1:4 swap ratio for the merger of the companies. - The company also set up a state of the art research centre named Sun Pharma advanced Research Centre (SPARC) in Vadodara. - Sun Pharmaceuticals to set a new tablet manufacturing facility at Silvassa in Dadra and Nagar Haveli as part of its strategy to maximize benefits on the tax shelter front. The new unit is expected to come up close to Sun's existing formulations facility at piparia in Silvassa. 1998 - During the year the company launched Duracard that not only affects Blood pressure but also has beneficial effect on the cholestrol profile and glucose metabolishm. - Another product launched was Cardivas, that has an ability to pump blood through the body there by reducing the strain on the heart during heart failure. - The company also launched Muvera, an anti inflammatory drug and Octapeptide Octride, an emergency medication in treating oesophagel varices, severe bleeding in the upper part of the gastrointestinal tract and also in the treatment of acromegaly an endocrine disorder caused by the excess growth of hormone secretion. - 2,08,000 shares of Rs. 10 each allotted to shareholders of erstwhile Milment Labs. Pvt. Ltd. Pursuant to a scheme of amalgamation. - Sun Pharmaceuticals Industries has converted its partnership export entity, Sun Pharma Exports, into a 100 per cent subsidiary, effective from 5th May. - Sun Pharma Exports, a partnership firm in which SPIL held 80 per cent stake, to Sunkalp Laboratories, a 100 per cent subsidiary of SPIL, with effect from 12th May. - In addition to this the company has set up state-of-the-art facilities for R&D in Baroda to carry out research in pharmaceuticals. 1999 - A leading Indian Company will set up a pharmaceutical plant in Bangladesh under a joint venture. - The hiving-off of Sun Pharmaceutical Exports into a 100 per cent subsidiary and increase in interest burden affected the bottomline. 2000 - The Company has merged its wholly owned export subsidiary Sun Pharma Exports with itself. - The Company is looking at an over 70 per cent growth rate in India, driven primarily by the company's products and education services segment. - As per the Scheme of Amalgamation, SPIL shall issue four equity shares of Rs 10 each of SPIL to the members of SPEL for every five equity shares held in SPEL. - The Company, on 1st April, allotted 3,08,44,466 Bonus Equity Shares of Rs. 10/- each, to the shaeholders of hte Company in the ratio o f 2 Bonus Equity shares for eveyr 1 Equity share held by the shareholders and Bonus equity Shares will be entitled to any dividend declared after 1st April. - The Company has launched Edegra (Sidenefil) in 25, 50 and 100mg. - During June 2000, the company introduced several products including Celact (celecoxib), Oleanz (olanzapine), Rofact (rofecoxib), Nodict (naltrexone), Fexotrol (fexofenadine), Zelast (azolastine) and (Ketorid(ketotifen). - In June 2000, Sun Pharma merged its 99.28% subsidiary - Sun Pharmaceuticals Exports. 2001 - Sun Pharmaceutical Industries Ltd has approved the merger of the ailing Pradeep Drug Company Ltd. - Sun Pharmaceutical Industries Ltd. is to merge its research arm Sun Pharmaceutical Advanced Research Centre Ltd. - During 2000-01, across the company's eight speciality divisions, 33 new products were launched. Taking the lead for new products among the therapy areas were cardiology (6 products), diabetology (4) and opthalmology (6). Likely brand outperformers among these are the antihypertensive Irovel (Rapilin, Pioglit, Rezult) for antidiabetics and the erectile dysfunction treatment Edegra. - The company, ranked 5th by domestic prescription product sales, has been consistently adding to market share from 2.47% in November 2000 to 2.78% in November 2001 (ORG Retail Chemist Audit, November 2000 and 2001). Forbes Global, the prestigious international magazine recently rated Sun Pharma among the best 200 global companies for 2002 (turnover less than $500mill). 2002 -Caraco Pharmaceutical Laboratories, associate of Sun Pharmaceuticals, has received US Food and Drug Authority (FDA) preliminary approval for metformin hydrochloride, a molecule used to treat diabetes. - Currently, the company is in process of merging Pradeep Drug Company (PDC) with itself. The company shareholders have approved the merger w.e.f. 1 April 2000. The scheme has been duly sanctioned by BIFR at its meeting held on Jan 2002. - Sun Pharma has made an open offer to the investors in Ahmedabad, Calcutta, Madras, Pondicherry and Delhi stock exchages to purchase the shares at price of Rs 600 per share. The offer is limited to those shareholders whose names are registered as members of the company as on 26/03/2002, the record date. -Sun Pharmaceutical Industries has launched Lupride Depot IM, a novel drug delivery system of prostate cancer drug leuprolide acetate, which would enabel the drug to be injected once in a month as against once in a day or once in three days drugs. -Mr Keki Mistry, Managing Director of HDFC, has been inducted into the board of directors of Sun Pharmaceuticals Industries Ltd. -The Board of Directors of Sun Pharmaceutical Industries Ltd at its meeting held allotted 18,71,77,232 6% Cumulative Redeemable Preference Shares of Re 1 each as Bonus Shares in the ratio of 4:1 (ie 4 Preference Shares of Re 1 each for every one equity shares of Rs 10 each) to the equity shareholders of the company as on the record date October 10, 2002. 2003 -Sun Pharmaceutical Industries Ltd (Sun Pharma) has announced the Buyback of fully paid-up equity shares of the Company of face value of Rs 10 each and / or Rs 5 each (being face value and paid up value subsequent to the splitting of the equity shares of Rs 10 into 2 equity shares) not exceeding 2,000,000 equity shares of Rs 10 each and/or 4,000,000 equity shares of Rs 5 each i.e. not exceeding equity shares of face value of Rs 20,000,000 being less than 25% of the paid-up equity share capital of the company for an aggregate amount not exceeding Rs 1200,000,000 upto a maximum price of Rs 750 per equity share of Rs 10 each or upto a maximum price of Rs 375 per equity share of Rs 5 each from the existing shareholders and beneficial owners of the shares of the company from open market through stock exchanges. -Sun Pharmaceuticals Industries Ltd has informed the Exchange that the Board of Directors at its meeting held on January 30, 2003 accepted the resignation of Shri R K Baheti, Senior Vice President - Finance and Company secretary of the Company w.e.f 31/1/2003 and the Board appointed Shri Kamlesh H Shah as the Company Secretary w.e.f. 31/1/2003. -Sun Pharmaceuticals' US-based associate, Caraco Pharmaceutical Laboratories, has received the approval from the US Food and Drug Administration (US FDA) to manufacture and market yet another generic drug, this time for the treatment of mild to moderate cardiac failure, in the US. The drug, Digoxin, is the generic form of Glaxo Wellcome's Lanoxin, the company said. -Sun Pharmaceutical Industries Ltd has informed BSE that it has further redeemed 1,42,99,833, 6% Cumulative Redeemable Preference Shares of Re 1 each amounting to Rs 1,42,99,833 in the fifth lot out of the total paid - up Preference Share Capital of the company. -Sun Pharmaceuticals Industries Ltd has informed the Exchange that the company pursuant to the earlier intimation about Redemption of Preference Shares, have extinguished /cancelled 3,01,20,608 shares - 6% Cumulative Redeemable Preference Shares of Re.1/- each consisting of 2,98,37,008 Preference Shares in demat mode and 2,93,376 Preference Shares in physical mode. -Board approved to close buy back of shares -The company's equity shares will be delisted from Vadodara Stock Exchange Ltd. 2004 - Sun Pharma acquires common stock and options from 2 large shareholders of Caraco, increasing stake to over 60% from 44% at a total outlay of about $42 million. By 2007, this stake has reached 75% on a diluted basis. The formulation site in Halol, India (the erstwhile MJ Pharma site) receives approval from USFDA, UK MHRA, South African MCC, Brazilian ANVISA and Columbian INVIMA. The BT Stern Stewart survey places Sun Pharma among the top 20 wealth creators in India and among the top 3 wealth creators in the pharma sector. Construction at a formulation manufacturing site at Jammu is completed. Our first joint venture manufacturing unit, in Dhaka, Bangladesh is commissioned. This modern site is spread over 25,000 sq. ft. - Two of Sun Pharma's API factories receive USFDA approval, taking the total number of US FDA approved sites to three. - Sun Pharma acquires a Cephalosporin Actives manufacturer, Phlox Pharma, with European approval for cefuroxime axetil amorphous. By 2007, a formulations facility to make sterile and non sterile formulations have been built, and the API and non-sterile sections have been approved by the USFDA. - Niche brands are bought from the San Diego, US based Women's First Healthcare. (WFHC, not listed). These brands are the gynecological Ortho-Estr (estropipate), and the antimigraine preparation Midrinr. - Forbes Global ranks Sun Pharma in the list of most valuable companies for 2004 (turnover less than $2bill). 2005 -Sun Pharma buys a plant in Bryan, Ohio, US and the business of ICN, Hungary from Valeant Pharma. -Sun Pharma acquires the intellectual property and assets of Able Labs from the US District Bankruptcy court in New Jersey in December 2005. -Dilip Shanghvi, the CMD, receives the E&Y Entrepreneur of the Year award in healthcare and life sciences for 2005. -Sun Pharma is selected by Forbes amongst the best 200 companies (sales less than USD 1 billion) in Asia. This is the fourth time in 5 years that the company has been selected. -Registered Office of the Company has been shifted From SPARC, Akota Road,Akota, Vadodara-390 020 To SPARC,Tandalja,Vadodara-390020. 2006 - Announced the demerger of innovative business with pipelines, people, equipment and funding, into a new company. 2007 - Completed the demerger of the innovative business, with requisite legal and regulatory approvals. SPARC ltd, the new company, is listed on the stock exchanges in India, the first pure research company to be so listed. - In May 2007, we, along with our subsidiaries, signed definitive agreements to acquire Taro Pharmaceutical Industries Ltd., (TAROF, Pink Sheets), a multinational generic manufacturer with established subsidiaries, manufacturing and products across the U.S., Israel, Canada for $454 mill. This all-cash deal is subject to Taro shareholder approval and requisite regulatory clearances 2008 -Sun Pharmaceutical Industries Ltd on January 30, 2008 announced that it has commercially launched generic Pantoprazole Sodium Delayed Release (DR) Tablets, 40 mg, which is AB-rated to Wyeth's Protonix DR Tablets. Sun's product is being sold in the United States by its marketing partner Caraco Pharmaceutical Laboratories. - In November 2008, we along with our subsidiaries, acquired 100% ownership of Chattem Chemicals, Inc.,a narcotic raw material importer and manufacturer of controlled substances with a approved facility in Tennessee. This will offer vertical integration for our controlled substance dosage form business in the US. 2010 - Sun Pharmaceutical Industries (Sun) has completed the acquisition of a controlling stake in Taro Pharmaceutical Industries (Taro) following the Option Agreement entered into in 2007 with Taro's controlling shareholders led by Taro's Chairman Barrie Levitt. - Sun Pharmaceutical on Sept 8 won a significant victory in its three-year-old battle to acquire Taro Pharmaceuticals. - Sun Pharma - Sun Pharma announced launch of generic Exelon in US - Sun Pharma - Supreme Court of Israel Rules in Favor of Sun Pharma -Company has splits its Face value of Shares from Rs 5 to Re 1 2011 - SunPharma - Merck & Co., Inc., and Sun Pharma Establish Joint Venture to Develop and Commercialize Novel Formulations and Combinations of Medicines in Emerging Markets. - SunPharma - MSD in India and Sun Pharmaceutical Industries Ltd entered Strategic Partnership to Co-market MSD's diabetes drug. - Merck & Co., Inc., and Sun Pharma Establish Joint Ventured to Develop and Commercialize Novel Formulations and Combinations of Medicines in Emerging Markets - Sun Pharma - MSD in India and Sun Pharmaceutical Industries Ltd Enter Strategic Partnership to Co-market MSD's diabetes drug. 2012 - Sun Pharma bagged USFDA approval for its AND Application for generic Zyprexa - Israel Makov appointed Chairman of Sun Pharma Board - Sun Pharma acquired URL generic business from Takeda - The Norwegian firm Telenor conduct its operations in India, promoters of Sun Pharma emerged as the new JV partner of the company. 2013 -Sun Pharma announces US FDA approval for generic Cymbaltar -Sun Pharma and Intrexon Form Joint Venture to Develop New Class of Therapeutics for Ocular Diseases -Sun Pharma announces USFDA approval for generic Prevacidr -Sun Pharma announces USFDA approval for generic DepoAr-Testosterone Injection -Sun Pharma Announces 1:1 Bonus -Sun pharma announces Tentative USFDA approval for generic Januvia & Glumetza -Sun Pharma announces USFDA approval for generic DoxilAr 2014 -Sun Pharma announces US FDA approval for generic Temodarr -Sun Pharma acquires Pharmalucence -Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab -Sun Pharma to acquire Ranbaxy in a US$ 4 billion landmark transaction 2015 -Sun Pharma receives US FTC clearance for Ranbaxy acquisition -Sun Pharma and AstraZeneca enter into distribution agreement for ticagrelor in India -SPARC Licenses Xelpros (Latanoprost BAK-free) to Sun Pharma -Hon'ble High Court of Gujarat, at Ahmedabad has approved the Scheme of Amalgamation of Sun Pharma Global Inc. (SPGI), wholly-owned subsidiary of the Company -Sun Pharma announces US FDA Approval for Ximino TM -Sun Pharma announces successful completion of Opiates business acquisition in Australia -Sun Pharma announces Absorica patent litigation settlement -Sun Pharma Successfully Acquires Insite Vision 2016 -Sun Pharma get CCI nod for CNS deal. - Sun Pharma launches Imatinib Mesylate in USA. -Sun Pharma acquires Novartis brands for Rs 1,900 cr. -Sun Pharma Receives USFDA Approval For BromSite. -Sun Pharma. - ICGEB & Sun Pharma sign an exclusive agreement to develop novel botanical drug for treatment of Dengue. -Sun Pharma launches sunscreen brand Suncros. -Sun Pharma launches Gemcitabine InfuSMART in Europe. -Sun Pharma receives approval for generic Glumetza. -Sun Pharma, ICGEB tie up to develop dengue vaccine. -Sun Pharma completes acquisition of Ocular Technologies. -Sun Pharma completes acquisition of 85% stake in JSC Biosintez. 2017 - Sun Pharma. - FDEC commences roll-out of Malaria demonstration project - Sun Pharma’s arm bags approval for new label for Odomzo - Sun Pharma gets EIR for Dadra formulation facility 2018 -Sun Pharma Launches Novel Drug Kapspargo Sprinkle in USA. -Sun Pharma bags CSR award from FGI. 2019 -Sun Pharma Launches Drizalma Sprinkle in the US. -Sun Pharma Launches Ready-to-Infuse INFUGEM in the U.S. 2020 -Sun Pharma launches FluGuard (Favipiravir) in India at Rs. 35 per tablet. -Sun Pharma Introduces ABSORICA LD Capsules for Management of Severe Recalcitrant Nodular Acne in the U.S. 2021 -Sun Pharma Launches Website for its Long Term Care Portfolio in the US. -Sun Pharma launches 'Sunkalp' on the occasion of National Doctors' Day. -Sun Pharma launches Chericof 12 in India, a novel formulation that provides relief from cough for up to 12 hours. 2022 -Sun Pharma and SPARC enter into a license agreement for commercialization of phenobarbital for injection in the US. -Sun Pharma and Cosmo Announce Territory Expansion of License and Supply Agreements for WINLEVI to include Japan. -Sun Pharma launches CEQUA the first dry eye treatment with nanomicellar (NCELL) technology in Canada. -Sun Pharma to introduce its version of Vortioxetine in India under an exclusive patent license from Lundbeck. -Sun Pharma Acquires Uractiv Portfolio from Fiterman Pharma in Romania. 2023 -Sun Pharma and Zydus sign licensing agreement for co-marketing of Desidustat in India. -Sun Pharma Announces US FDA Filing Acceptance of New Drug Application For Deuruxolitinib. -Sun Pharma Canada Launches PR WINLEVIr (clascoterone cream 1% w/w), a Novel Topical Treatment for Acne. -Sun Pharma and Pharmazz Inc. enter into licensing agreement for introducing Tyvalzi.(Sovateltide) in India. -Sun Pharma launches nationwide initiative, Second Birth Date on National Doctor's Day.
1983 - The Company was incorporated as a partnership firm by Dilip Sanghvi & his family to manufacture pharmaceutical formulation at Vapi, Gujarat. It was converted into a public Ltd. Company effective 1st March. The was promoted by Dilip Sanghvi. The Company specialises in selected therapeutic segment to psychiatry, cardiology, neurology and gastroenterology. 1994 - The Bulk drug plant at Panoli was commissioned. The second formulation plant at Silvana was commissioned in April. - During October, the company undertook to enhance the production capacity of bulk drugs at Panoli from 62,000 Kgs. p.a. to 92000 Kgs. p.a. Also formulation unit was to be enhanced to 1800 millions tablets p.a. from 570 million tablets p.a. - The Company proposed to modernise the formulation unit at Vapi and increase its capacity from 480 million tablets to 1440 million tablets p.a. It was also proposed to set up additional facilities at the R&D centre SPARC. - 71,85,000 No. of equity shares issued to promoters etc. 1995 - In the synergy division two more products viz. `Clofranil SR and Syndopa CR were introduced. - The Company entered into a MOU with Knoll Pharmaceuticals Ltd. for acquisition of their Ahmednagar unit manufacturing bulk drugs. - 35,92,500 No. of equity shares allotted as bonus shares in prop 1:2. 3,23,400 Rights shares issued at a premium of Rs 130 per shares.During October 1994, the capital issued 37,00,300 No. of equity shares of Rs 10 each at a premium of Rs 140 per share to the public. 1996 - 18 new products were launched across the company's six focused marketing divisions and 4 more line extension including drug delivery systems were launched. - The Company acquired controlling stake in MJ Pharmaceuticals Ltd. - SPIL and its group company Virtuous Finance Ltd., which are the the major shareholders of MJPL with more than 50 per cent of shareholding, had signed a MoU with erstwhile promoters the Shah family, on November 1. 1997 - The Company acquired 78,36,000 No. of equity shares of Rs 10 each. - The Chennai based Tamil Nadu Dadha Pharmaceuticals Co. Ltd. was merged with the company in the ratio of 4:1 effective 1st April. With this, IDPL brings to sun pharma extensive product strengths across the areas of gynaecology, fertility, oncology, pain mengeners and duaesthelics. - Sunkalp Laboratories Ltd., Sun Pharma Industries Ltd., Russia & Sun Pharma Global Inc. are all subsidiaries of the Company. - 4,13,633 No. of equity shares allotted to erstwhile shareholders of Tamil Nadu, Dadha Pharmaceuticals pursuant to a scheme of amalgamation. - The boards of Tamilnadu Dadha Pharmaceuticals Ltd. (TDPL) and Sun Pharmaceuticals Ltd. have approved a 1:4 swap ratio for the merger of the companies. - The company also set up a state of the art research centre named Sun Pharma advanced Research Centre (SPARC) in Vadodara. - Sun Pharmaceuticals to set a new tablet manufacturing facility at Silvassa in Dadra and Nagar Haveli as part of its strategy to maximize benefits on the tax shelter front. The new unit is expected to come up close to Sun's existing formulations facility at piparia in Silvassa. 1998 - During the year the company launched Duracard that not only affects Blood pressure but also has beneficial effect on the cholestrol profile and glucose metabolishm. - Another product launched was Cardivas, that has an ability to pump blood through the body there by reducing the strain on the heart during heart failure. - The company also launched Muvera, an anti inflammatory drug and Octapeptide Octride, an emergency medication in treating oesophagel varices, severe bleeding in the upper part of the gastrointestinal tract and also in the treatment of acromegaly an endocrine disorder caused by the excess growth of hormone secretion. - 2,08,000 shares of Rs. 10 each allotted to shareholders of erstwhile Milment Labs. Pvt. Ltd. Pursuant to a scheme of amalgamation. - Sun Pharmaceuticals Industries has converted its partnership export entity, Sun Pharma Exports, into a 100 per cent subsidiary, effective from 5th May. - Sun Pharma Exports, a partnership firm in which SPIL held 80 per cent stake, to Sunkalp Laboratories, a 100 per cent subsidiary of SPIL, with effect from 12th May. - In addition to this the company has set up state-of-the-art facilities for R&D in Baroda to carry out research in pharmaceuticals. 1999 - A leading Indian Company will set up a pharmaceutical plant in Bangladesh under a joint venture. - The hiving-off of Sun Pharmaceutical Exports into a 100 per cent subsidiary and increase in interest burden affected the bottomline. 2000 - The Company has merged its wholly owned export subsidiary Sun Pharma Exports with itself. - The Company is looking at an over 70 per cent growth rate in India, driven primarily by the company's products and education services segment. - As per the Scheme of Amalgamation, SPIL shall issue four equity shares of Rs 10 each of SPIL to the members of SPEL for every five equity shares held in SPEL. - The Company, on 1st April, allotted 3,08,44,466 Bonus Equity Shares of Rs. 10/- each, to the shaeholders of hte Company in the ratio o f 2 Bonus Equity shares for eveyr 1 Equity share held by the shareholders and Bonus equity Shares will be entitled to any dividend declared after 1st April. - The Company has launched Edegra (Sidenefil) in 25, 50 and 100mg. - During June 2000, the company introduced several products including Celact (celecoxib), Oleanz (olanzapine), Rofact (rofecoxib), Nodict (naltrexone), Fexotrol (fexofenadine), Zelast (azolastine) and (Ketorid(ketotifen). - In June 2000, Sun Pharma merged its 99.28% subsidiary - Sun Pharmaceuticals Exports. 2001 - Sun Pharmaceutical Industries Ltd has approved the merger of the ailing Pradeep Drug Company Ltd. - Sun Pharmaceutical Industries Ltd. is to merge its research arm Sun Pharmaceutical Advanced Research Centre Ltd. - During 2000-01, across the company's eight speciality divisions, 33 new products were launched. Taking the lead for new products among the therapy areas were cardiology (6 products), diabetology (4) and opthalmology (6). Likely brand outperformers among these are the antihypertensive Irovel (Rapilin, Pioglit, Rezult) for antidiabetics and the erectile dysfunction treatment Edegra. - The company, ranked 5th by domestic prescription product sales, has been consistently adding to market share from 2.47% in November 2000 to 2.78% in November 2001 (ORG Retail Chemist Audit, November 2000 and 2001). Forbes Global, the prestigious international magazine recently rated Sun Pharma among the best 200 global companies for 2002 (turnover less than $500mill). 2002 -Caraco Pharmaceutical Laboratories, associate of Sun Pharmaceuticals, has received US Food and Drug Authority (FDA) preliminary approval for metformin hydrochloride, a molecule used to treat diabetes. - Currently, the company is in process of merging Pradeep Drug Company (PDC) with itself. The company shareholders have approved the merger w.e.f. 1 April 2000. The scheme has been duly sanctioned by BIFR at its meeting held on Jan 2002. - Sun Pharma has made an open offer to the investors in Ahmedabad, Calcutta, Madras, Pondicherry and Delhi stock exchages to purchase the shares at price of Rs 600 per share. The offer is limited to those shareholders whose names are registered as members of the company as on 26/03/2002, the record date. -Sun Pharmaceutical Industries has launched Lupride Depot IM, a novel drug delivery system of prostate cancer drug leuprolide acetate, which would enabel the drug to be injected once in a month as against once in a day or once in three days drugs. -Mr Keki Mistry, Managing Director of HDFC, has been inducted into the board of directors of Sun Pharmaceuticals Industries Ltd. -The Board of Directors of Sun Pharmaceutical Industries Ltd at its meeting held allotted 18,71,77,232 6% Cumulative Redeemable Preference Shares of Re 1 each as Bonus Shares in the ratio of 4:1 (ie 4 Preference Shares of Re 1 each for every one equity shares of Rs 10 each) to the equity shareholders of the company as on the record date October 10, 2002. 2003 -Sun Pharmaceutical Industries Ltd (Sun Pharma) has announced the Buyback of fully paid-up equity shares of the Company of face value of Rs 10 each and / or Rs 5 each (being face value and paid up value subsequent to the splitting of the equity shares of Rs 10 into 2 equity shares) not exceeding 2,000,000 equity shares of Rs 10 each and/or 4,000,000 equity shares of Rs 5 each i.e. not exceeding equity shares of face value of Rs 20,000,000 being less than 25% of the paid-up equity share capital of the company for an aggregate amount not exceeding Rs 1200,000,000 upto a maximum price of Rs 750 per equity share of Rs 10 each or upto a maximum price of Rs 375 per equity share of Rs 5 each from the existing shareholders and beneficial owners of the shares of the company from open market through stock exchanges. -Sun Pharmaceuticals Industries Ltd has informed the Exchange that the Board of Directors at its meeting held on January 30, 2003 accepted the resignation of Shri R K Baheti, Senior Vice President - Finance and Company secretary of the Company w.e.f 31/1/2003 and the Board appointed Shri Kamlesh H Shah as the Company Secretary w.e.f. 31/1/2003. -Sun Pharmaceuticals' US-based associate, Caraco Pharmaceutical Laboratories, has received the approval from the US Food and Drug Administration (US FDA) to manufacture and market yet another generic drug, this time for the treatment of mild to moderate cardiac failure, in the US. The drug, Digoxin, is the generic form of Glaxo Wellcome's Lanoxin, the company said. -Sun Pharmaceutical Industries Ltd has informed BSE that it has further redeemed 1,42,99,833, 6% Cumulative Redeemable Preference Shares of Re 1 each amounting to Rs 1,42,99,833 in the fifth lot out of the total paid - up Preference Share Capital of the company. -Sun Pharmaceuticals Industries Ltd has informed the Exchange that the company pursuant to the earlier intimation about Redemption of Preference Shares, have extinguished /cancelled 3,01,20,608 shares - 6% Cumulative Redeemable Preference Shares of Re.1/- each consisting of 2,98,37,008 Preference Shares in demat mode and 2,93,376 Preference Shares in physical mode. -Board approved to close buy back of shares -The company's equity shares will be delisted from Vadodara Stock Exchange Ltd. 2004 - Sun Pharma acquires common stock and options from 2 large shareholders of Caraco, increasing stake to over 60% from 44% at a total outlay of about $42 million. By 2007, this stake has reached 75% on a diluted basis. The formulation site in Halol, India (the erstwhile MJ Pharma site) receives approval from USFDA, UK MHRA, South African MCC, Brazilian ANVISA and Columbian INVIMA. The BT Stern Stewart survey places Sun Pharma among the top 20 wealth creators in India and among the top 3 wealth creators in the pharma sector. Construction at a formulation manufacturing site at Jammu is completed. Our first joint venture manufacturing unit, in Dhaka, Bangladesh is commissioned. This modern site is spread over 25,000 sq. ft. - Two of Sun Pharma's API factories receive USFDA approval, taking the total number of US FDA approved sites to three. - Sun Pharma acquires a Cephalosporin Actives manufacturer, Phlox Pharma, with European approval for cefuroxime axetil amorphous. By 2007, a formulations facility to make sterile and non sterile formulations have been built, and the API and non-sterile sections have been approved by the USFDA. - Niche brands are bought from the San Diego, US based Women's First Healthcare. (WFHC, not listed). These brands are the gynecological Ortho-Estr (estropipate), and the antimigraine preparation Midrinr. - Forbes Global ranks Sun Pharma in the list of most valuable companies for 2004 (turnover less than $2bill). 2005 -Sun Pharma buys a plant in Bryan, Ohio, US and the business of ICN, Hungary from Valeant Pharma. -Sun Pharma acquires the intellectual property and assets of Able Labs from the US District Bankruptcy court in New Jersey in December 2005. -Dilip Shanghvi, the CMD, receives the E&Y Entrepreneur of the Year award in healthcare and life sciences for 2005. -Sun Pharma is selected by Forbes amongst the best 200 companies (sales less than USD 1 billion) in Asia. This is the fourth time in 5 years that the company has been selected. -Registered Office of the Company has been shifted From SPARC, Akota Road,Akota, Vadodara-390 020 To SPARC,Tandalja,Vadodara-390020. 2006 - Announced the demerger of innovative business with pipelines, people, equipment and funding, into a new company. 2007 - Completed the demerger of the innovative business, with requisite legal and regulatory approvals. SPARC ltd, the new company, is listed on the stock exchanges in India, the first pure research company to be so listed. - In May 2007, we, along with our subsidiaries, signed definitive agreements to acquire Taro Pharmaceutical Industries Ltd., (TAROF, Pink Sheets), a multinational generic manufacturer with established subsidiaries, manufacturing and products across the U.S., Israel, Canada for $454 mill. This all-cash deal is subject to Taro shareholder approval and requisite regulatory clearances 2008 -Sun Pharmaceutical Industries Ltd on January 30, 2008 announced that it has commercially launched generic Pantoprazole Sodium Delayed Release (DR) Tablets, 40 mg, which is AB-rated to Wyeth's Protonix DR Tablets. Sun's product is being sold in the United States by its marketing partner Caraco Pharmaceutical Laboratories. - In November 2008, we along with our subsidiaries, acquired 100% ownership of Chattem Chemicals, Inc.,a narcotic raw material importer and manufacturer of controlled substances with a approved facility in Tennessee. This will offer vertical integration for our controlled substance dosage form business in the US. 2010 - Sun Pharmaceutical Industries (Sun) has completed the acquisition of a controlling stake in Taro Pharmaceutical Industries (Taro) following the Option Agreement entered into in 2007 with Taro's controlling shareholders led by Taro's Chairman Barrie Levitt. - Sun Pharmaceutical on Sept 8 won a significant victory in its three-year-old battle to acquire Taro Pharmaceuticals. - Sun Pharma - Sun Pharma announced launch of generic Exelon in US - Sun Pharma - Supreme Court of Israel Rules in Favor of Sun Pharma -Company has splits its Face value of Shares from Rs 5 to Re 1 2011 - SunPharma - Merck & Co., Inc., and Sun Pharma Establish Joint Venture to Develop and Commercialize Novel Formulations and Combinations of Medicines in Emerging Markets. - SunPharma - MSD in India and Sun Pharmaceutical Industries Ltd entered Strategic Partnership to Co-market MSD's diabetes drug. - Merck & Co., Inc., and Sun Pharma Establish Joint Ventured to Develop and Commercialize Novel Formulations and Combinations of Medicines in Emerging Markets - Sun Pharma - MSD in India and Sun Pharmaceutical Industries Ltd Enter Strategic Partnership to Co-market MSD's diabetes drug. 2012 - Sun Pharma bagged USFDA approval for its AND Application for generic Zyprexa - Israel Makov appointed Chairman of Sun Pharma Board - Sun Pharma acquired URL generic business from Takeda - The Norwegian firm Telenor conduct its operations in India, promoters of Sun Pharma emerged as the new JV partner of the company. 2013 -Sun Pharma announces US FDA approval for generic Cymbaltar -Sun Pharma and Intrexon Form Joint Venture to Develop New Class of Therapeutics for Ocular Diseases -Sun Pharma announces USFDA approval for generic Prevacidr -Sun Pharma announces USFDA approval for generic DepoAr-Testosterone Injection -Sun Pharma Announces 1:1 Bonus -Sun pharma announces Tentative USFDA approval for generic Januvia & Glumetza -Sun Pharma announces USFDA approval for generic DoxilAr 2014 -Sun Pharma announces US FDA approval for generic Temodarr -Sun Pharma acquires Pharmalucence -Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab -Sun Pharma to acquire Ranbaxy in a US$ 4 billion landmark transaction 2015 -Sun Pharma receives US FTC clearance for Ranbaxy acquisition -Sun Pharma and AstraZeneca enter into distribution agreement for ticagrelor in India -SPARC Licenses Xelpros (Latanoprost BAK-free) to Sun Pharma -Hon'ble High Court of Gujarat, at Ahmedabad has approved the Scheme of Amalgamation of Sun Pharma Global Inc. (SPGI), wholly-owned subsidiary of the Company -Sun Pharma announces US FDA Approval for Ximino TM -Sun Pharma announces successful completion of Opiates business acquisition in Australia -Sun Pharma announces Absorica patent litigation settlement -Sun Pharma Successfully Acquires Insite Vision 2016 -Sun Pharma get CCI nod for CNS deal. - Sun Pharma launches Imatinib Mesylate in USA. -Sun Pharma acquires Novartis brands for Rs 1,900 cr. -Sun Pharma Receives USFDA Approval For BromSite. -Sun Pharma. - ICGEB & Sun Pharma sign an exclusive agreement to develop novel botanical drug for treatment of Dengue. -Sun Pharma launches sunscreen brand Suncros. -Sun Pharma launches Gemcitabine InfuSMART in Europe. -Sun Pharma receives approval for generic Glumetza. -Sun Pharma, ICGEB tie up to develop dengue vaccine. -Sun Pharma completes acquisition of Ocular Technologies. -Sun Pharma completes acquisition of 85% stake in JSC Biosintez. 2017 - Sun Pharma. - FDEC commences roll-out of Malaria demonstration project - Sun Pharma’s arm bags approval for new label for Odomzo - Sun Pharma gets EIR for Dadra formulation facility 2018 -Sun Pharma Launches Novel Drug Kapspargo Sprinkle in USA. -Sun Pharma bags CSR award from FGI. 2019 -Sun Pharma Launches Drizalma Sprinkle in the US. -Sun Pharma Launches Ready-to-Infuse INFUGEM in the U.S. 2020 -Sun Pharma launches FluGuard (Favipiravir) in India at Rs. 35 per tablet. -Sun Pharma Introduces ABSORICA LD Capsules for Management of Severe Recalcitrant Nodular Acne in the U.S. 2021 -Sun Pharma Launches Website for its Long Term Care Portfolio in the US. -Sun Pharma launches 'Sunkalp' on the occasion of National Doctors' Day. -Sun Pharma launches Chericof 12 in India, a novel formulation that provides relief from cough for up to 12 hours. 2022 -Sun Pharma and SPARC enter into a license agreement for commercialization of phenobarbital for injection in the US. -Sun Pharma and Cosmo Announce Territory Expansion of License and Supply Agreements for WINLEVI to include Japan. -Sun Pharma launches CEQUA the first dry eye treatment with nanomicellar (NCELL) technology in Canada. -Sun Pharma to introduce its version of Vortioxetine in India under an exclusive patent license from Lundbeck. -Sun Pharma Acquires Uractiv Portfolio from Fiterman Pharma in Romania. 2023 -Sun Pharma and Zydus sign licensing agreement for co-marketing of Desidustat in India. -Sun Pharma Announces US FDA Filing Acceptance of New Drug Application For Deuruxolitinib. -Sun Pharma Canada Launches PR WINLEVIr (clascoterone cream 1% w/w), a Novel Topical Treatment for Acne. -Sun Pharma and Pharmazz Inc. enter into licensing agreement for introducing Tyvalzi.(Sovateltide) in India. -Sun Pharma launches nationwide initiative, Second Birth Date on National Doctor's Day.
Read More
Parent Organisation
Sun Pharmaceutical Industries Ltd.
Founded
01/03/1993
Managing Director
Mr.Dilip S Shanghvi
NSE Symbol
SUNPHARMAEQ
FAQ
The current price of Sun Pharmaceutical Industries Ltd is ₹ 1683.45.
The 52-week high for Sun Pharmaceutical Industries Ltd is ₹ 1687.15 and the 52-week low is ₹ 1663.45.
The market capitalization of Sun Pharmaceutical Industries Ltd is currently ₹ 403916.05. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Sun Pharmaceutical Industries Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Sun Pharmaceutical Industries Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Sun Pharmaceutical Industries Ltd shares.
The CEO of Sun Pharmaceutical Industries Ltd is Mr.Dilip S Shanghvi, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.